Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas

Journal of Clinical Pathology

Volumn 57, Issue 12, 2004, Pages 1306-1311

  Ishii, H H ^a   Gobe, G C ^b   Yoneyama, J ^a   Mukaide, M ^a   Ebihara, Y ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; STOMACH TUMOR; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

ADENOCARCINOMA; APOPTOSIS; CELL DIVISION; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 10044272279     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.015081     Document Type: Article

References (40)

1. zur Hausen H. Viruses in human cancers. Science 1991;254:1167-73.
2. Bréchot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinoma in Europe: results of a European concerted action. J Hepatol 1998;29:173-83.
3. Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells From death by apoptosis. Nature 1991;349:612-14.
4. Ishii H, Tamauchi H, Gobe CG. In the absence of Epstein-Barr virus infection, phorbol ester modulates apoptosis in cycloheximide-treated Burkitt's lymphoma (BJA-B) cells. Int J Exp Pathol 1997;78:123-31.
5. Mauser A, Saito S, Appelle E, et al. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 2002;76:12503-12.
6. Iamaroon A, Pongsiriwet S, Mahanupad P, et al. Oral non-Hodgkin lymphomas: studies of EBV and p53 expression. Oral Dis 2003;9:14-8.
7. Lane DP. p53 and human cancers. Br Med Bull 1994;50:582-99.
8. Liu MC, Gelmann EP. p53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002;29:246-57.
9. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003;36:165-75.
10. Leung SY, Chau KY, Yuen ST, et al. p53 overexpression is different in Epstein-Barr virus-associated and Epstein-Barr virus-negative carcinoma. Histopathology 1998;33:311-17.
11. Moritani S, Sugihara H, Kushima R, et al. Different roles of p53 between Epstein-Barr virus-positive and -negative gastric carcinomas of matched histology. Virchows Arch 2002;440:367-75.
12. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4.
13. Doniger J, Muralidhar S, Rosenthal LJ. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev 1999;12:367-82.
14. Park J, Seo T, Hwang S, et al. The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. J Virol 2000;74:11977-82.
15. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996;70:8653-9.
16. Friborg Jr J, Kong W-p, Hottiger MO, et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889-94.
17. Kijima Y, Ishigami S, Hokita S, et al. The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. Cancer Lett 2003;200:33-40.
18. Ohfuji S, Osaki M, Tsujitani S, et al. Low frequency of apoptosis in Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma. Int J Cancer 1996;68:710-15.
19. Komano J, Maruo S, Kurozumi K, et al. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999;73:9827-31.
20. International Union Against Cancer, Sobin LH, Wittekind CH, eds. TNM classification of malignant tumors, 5th ed. New York: John Wiley & Sons, 1997.
21. Soong R, Robbins PD, Dix BR, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5.
22. Kerr J, Gobe GC, Winterford CM, et al. Anatomical methods in cell death. Methods Cell Biol 1995;46:1-27.
23. Ishii HH, Gobe GC, Pan W, et al. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 expression. J Gastroenterol Hepatol 2002;17:966-72.
24. Gobe G, Zhang X-J, Willgoss DA, et al. Relationship between expression of bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol 2000;11:454-67.
25. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, et al. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995;21:1465-8.
26. Landberg G, Roos G. Proliferating cell nuclear antigen and Ki-67 antigen expression in human haematopoietic cells during growth stimulation and differentiation. Cell Prolif 1993;26:427-37.
27. Cohen JI. Epstein-Barr virus and the immune system hide and seek. JAMA 1997;278:510-13.
28. Epstein MA. Infection and tumor induction. Nature 1986;321:653-4.
29. Silins SL, Sculley TB. Burkitt's lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen EBNA-4. Int J Cancer 1995;60:65-72.
30. Gulley MI, Pulitzer DR, Eagan PA, et al. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996;27:20-7.
31. Lu Q-L, Elia G, Lucas S, et al. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993;53:29-35.
32. Yamamoto N, Tokunaga M, Uemura Y, et al. Epstein-Barr virus and gastric remnant cancer. Cancer 1994;74:805-9.
33. Chang Y-L, Wu C-T, Shih J-Y, et al. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol 2002;26:715-23.
34. van Rees BP, Caspers E, zur Hausen A, et al. Different patterns of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway. Am J Pathol 2002;161:1207-13.
35. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
36. Fagard R, Mouas H, Dusanter-Fourt I, et al. Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells. Oncogene 2002;21:4473-80.
37. Hiroshima K, Iyoda A, Toyozaki T, et al. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol 2002;15:1326-32.
38. Aizawa K, Ueki K, Suzuki S, et al. Apoptosis and bcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression cell proliferation and prognosis. Int J Oncol 1999;14:85-91.
39. Hong S-I, Hong W-S, Jang J-J, et al. Alterations of p53 gene in primary gastric cancer tissue. Anticancer Res 1994;14:1251-5.
40. Renault B, van den Broek M, Fodde R, et al. Base transitions are the most frequent genetic change cit p53 in gastric cancer. Cancer Res 1993;53:2614-17.